Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 31;11(6):816.
doi: 10.3390/biom11060816.

Buprenorphine: Far Beyond the "Ceiling"

Rosmara Infantino  1 , Consalvo Mattia  2   3 , Pamela Locarini  2 , Antonio Luigi Pastore  3   4 , Sabatino Maione  1   5 , Livio Luongo  1   5
Affiliations
Review

Buprenorphine: Far Beyond the "Ceiling"

Rosmara Infantino et al. Biomolecules. .

Abstract

Chronic pain, including neuropathic pain, represents an untreated disease with important repercussions on the quality of life and huge costs on the national health system. It is well known that opioids are the most powerful analgesic drugs, but they represent the second or third line in neuropathic pain, that remain difficult to manage. Moreover, these drugs show several side effects that limit their use. In addition, opioids possess addictive properties that are associated with misuse and drug abuse. Among available opioids compounds, buprenorphine has been suggested advantageous for a series of clinical reasons, including the effectiveness in neuropathic pain. Some properties are partly explained by its unique pharmacological characteristics. However, questions on the dynamic profile remain to be answered. Pharmacokinetics optimization strategies, and additional potentialities, are still to be explored. In this paper, we attempt to conceptualize the potential undiscovered dynamic profile of buprenorphine.

Keywords: biased agonist; buprenorphine; chronic pain; protean agonist.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Colloca L., Ludman T., Bouhassira D., Baron R., Dickenson A.H., Yarnitsky D., Freeman R., Truini A., Attal N., Finnerup N.B., et al. Neuropathic pain. Nat. Rev. Dis. Prim. 2017;3:1–19. doi: 10.1038/nrdp.2017.2. - DOI - PMC - PubMed
    1. Finnerup N.B., Otto M., McQuay H.J., Jensen T.S., Sindrup S.H. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain. 2005;118:289–305. doi: 10.1016/j.pain.2005.08.013. - DOI - PubMed
    1. Gierthmühlen J., Baron R. Neuropathic Pain. Semin. Neurol. 2016;36:462–468. doi: 10.1055/s-0036-1584950. - DOI - PubMed
    1. Moisset X., Bouhassira D., Avez Couturier J., Alchaar H., Conradi S., Delmotte M.H., Lanteri-Minet M., Lefaucheur J.P., Mick G., Piano V., et al. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev. Neurol. 2020;176:325–352. doi: 10.1016/j.neurol.2020.01.361. - DOI - PubMed
    1. Pergolizzi J.V., Jr., Scholten W., Smith K.J., Leighton-Scott J., Willis J.C., Henningfield J.E. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiol. Taiwanica. 2015;53:71–76. doi: 10.1016/j.aat.2015.06.001. - DOI - PubMed

Publication types